New hope for advanced colorectal cancer: targeted drug M9140 enters early trial
NCT ID NCT06806046
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This early-phase study tests an experimental drug called M9140 in 12 Chinese patients with advanced colorectal cancer that has not responded to standard treatments. The drug works like a guided missile, delivering chemotherapy directly to cancer cells that carry a specific marker (CEACAM5). The main goals are to check safety and see if the drug can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
-
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?